Research output per year
Research output per year
Personal profile
Personal webpage
Biography
Karijn Suijkerbuijk is a translational medical oncologist with special interest in melanoma and immunotherapy. During her PhD, she performed research on tumor epigenetics in breast cancer in the lab of Professor Saraswati Sukumar at the Sidney Kimmel Cancer Center at Johns Hopkins University. Dr. Suijkerbuijk currently participates in multiple phase II and III clinical trials on immune checkpoint inhibitors. She published papers in Oncogene, Annals of Oncology and JNCI, received research grants from KWF and NWO and was awarded an ASCO Merit Award. Her current research focuses on clinical and immunological parameters assoaciated with immune related adverse events during checkpoint inhibition and clinicopathological factors associated with checkpoint inhibitor response.
Fellowship & awards
2007 Research year for residents (UU2007-3977) KWF
2008 Translational grant KWF (UU-2008-4217
2008 AGIKO stipend, ZonMW
2008 ASCO Merit Award
2018 ZonMW goed gebruik geneesmiddelen
Education/Academic qualification
Associate Professor, University Medical Center (UMC) Utrecht
Award Date: 1 Nov 2019
External positions
research funding Genmab - AI onderzoekssamenwerking in Health Holland project dat door Genmab financieel wordt ondersteund - Genmab
1 Nov 2023 → 31 Dec 3999
ESMO melanoma faculty - expertise melanoom - European Society for Medical Oncology
13 Jun 2022 → 31 Dec 3999
Lid real world data working group ESMO - onderzoek patientcohorten - European Society for Medical Oncology
10 Jun 2022 → 31 Dec 3999
Lid wetenschappelijke adviesraad - ervaring onderzoek - Maarten van der Weijden foundation
10 Jun 2022 → 31 Dec 3999
Adviesraad stichting melanoom (sinds 2019) - Vanuit expertise als melanoombehandelaar - Stichting melanoom
9 Jun 2022 → 31 Dec 3999
Lid Data Safety Monitoring Committee CHOPIN studie (vanaf 2020; studie gesponsord door BMS) - onderzoekservaring immuuntherapie - LUMC
9 Jun 2022 → 31 Dec 3999
Voorzitter wetenschappelijke commissie - Kwaliteitsverbetering en onderzoek op het gebied van melanoomzorg - Dutch Melanoma Treatment Registry (DICA)
6 Jun 2022 → 31 Dec 3999
Adviesgroep kanker in de zwangerschap - Expertise melanoom en immuuntherapie - Adviesgroep kanker in de zwangerschap
1 Jun 2022 → 31 Dec 3999
Organisatie/voorzitter jaarlijks immuno-oncologie symposium - expertise en onderzoek immuunoncologie - Immuno-oncologie symposium
1 Jan 2020 → 31 Dec 3999
Bestuurslid Tumorfocusgroep melanoom - expertise melanoom - Tumorfocusgroep melanoom
1 Jan 2019 → 31 Dec 3999
medisch expert bij melanoom nascholing en congresjournaal ASCO/ESMO - expertise melanoom - Medtalks
1 Jan 2018 → 31 Dec 3999
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Adjuvant BRAF/MEK versus anti-PD-1 in BRAF-mutant melanoma: a propensity score matched survival analysis: Clinical Studies
Bloem, M., de Meza, M. M., van den Eertwegh, A. J. M., Aarts, M. J. B., van den Berkmortel, F. W. P. J., Blank, C. U., Blokx, W. A. M., Boers-Sonderen, M. J., Bonenkamp, J. J., Boreel, C. D. M., de Groot, J. W. B., Haanen, J. B. A. G., Hospers, G. A. P., Kapiteijn, E., van Not, O. J., Piersma, D., Rikhof, B., Stevense-den Boer, A. M., van der Veldt, A. A. M. & Vreugdenhil, G. & 2 others, , Jun 2025, In: British Journal of Cancer. 132, 12, p. 1124-1130 7 p., 102290.Research output: Contribution to journal › Article › Academic › peer-review
-
A novel dataset for nuclei and tissue segmentation in melanoma with baseline nuclei segmentation and tissue segmentation benchmarks
Schuiveling, M., Liu, H., Eek, D., Breimer, G. E., Suijkerbuijk, K. P. M., Blokx, W. A. M. & Veta, M., 6 Jan 2025, In: GigaScience. 14, p. 1-12 12 p., giaf011.Research output: Contribution to journal › Article › Academic › peer-review
Open AccessFile3 Downloads (Pure) -
Anti-PD-1 treatment response is associated with the influx of circulating myeloid and T-cell subsets into the metastatic melanoma tumor microenvironment
Van Dam, S., Krijgsman, D., Küçükköse, E., Verdonschot, M. E. L., Amini, M., Blokx, W. A. M., Van Eijs, M. J. M., Verheijden, R. J., Kranenburg, O., Suijkerbuijk, K. P. M., Leusen, J. H. W. & Vercoulen, Y., Nov 2025, In: British Journal of Cancer. 133, 9, p. 1250-1264 15 p.Research output: Contribution to journal › Article › Academic › peer-review
Open AccessFile -
Blood and tissue correlates of steroid non-response in checkpoint inhibition-induced immune-related adverse events
UNICIT consortium, 18 Nov 2025, In: Communications medicine. 5, 1, p. 1-14 14 p., 472.Research output: Contribution to journal › Article › Academic › peer-review
Open AccessFile1 Downloads (Pure) -
Body composition and checkpoint inhibitor treatment outcomes in advanced melanoma: a multicenter cohort study
Schuiveling, M., Ter Maat, L. S., Van Duin, I. A. J., Verheijden, R. J., Troenokarso, M. F., Moeskops, P., Verhoeff, J. J. C., Elias, S. G., Van Amsterdam, W. A. C., Burgers, F., Van Den Berkmortel, F. W. P. J., Boers-Sonderen, M. J., Boomsma, M. F., De Groot, J. W., Haanen, J. B. A. G., Hospers, G. A. P., Piersma, D., Vreugdenhil, G., Westgeest, H. M. & Kapiteijn, E. & 8 others, , 1 Jun 2025, In: Journal of the National Cancer Institute. 117, 6, p. 1245-1252 8 p.Research output: Contribution to journal › Article › Academic › peer-review
Open AccessFile1 Downloads (Pure)